BR112018069332A2 - composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncer - Google Patents
composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncerInfo
- Publication number
- BR112018069332A2 BR112018069332A2 BR112018069332A BR112018069332A BR112018069332A2 BR 112018069332 A2 BR112018069332 A2 BR 112018069332A2 BR 112018069332 A BR112018069332 A BR 112018069332A BR 112018069332 A BR112018069332 A BR 112018069332A BR 112018069332 A2 BR112018069332 A2 BR 112018069332A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- preventing cancer
- fragment
- cancer
- antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 239000012634 fragment Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
um objeto da presente invenção é identificar proteínas antigênicas de câncer expressas especificamente na superfície de células de câncer e proporcionar o uso de anticorpos direcionados a tais proteínas como agentes terapêuticos e/ou preventivos para o câncer. a presente invenção diz respeito, por exemplo, a uma composição farmacêutica para o tratamento e/ou a prevenção de um câncer que compreende como ingrediente ativo um anticorpo ou fragmento do mesmo que possui reatividade imunológica para uma proteína mcemp1 que possui a sequência de aminoácidos mostrada na em qualquer uma das seq id nos: 2 a 8 de números pares ou uma sequência de aminoácidos com 80% ou mais de identidade de sequência com tais sequências de aminoácidos, ou para um fragmento da proteína mcemp1 compreendendo 7 ou mais aminoácidos consecutivos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016064035 | 2016-03-28 | ||
| PCT/JP2017/012239 WO2017170322A1 (ja) | 2016-03-28 | 2017-03-27 | 癌の治療及び／又は予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018069332A2 true BR112018069332A2 (pt) | 2019-01-22 |
Family
ID=59965522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018069332A BR112018069332A2 (pt) | 2016-03-28 | 2017-03-27 | composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11492410B2 (pt) |
| EP (1) | EP3437655A4 (pt) |
| JP (1) | JP7037045B2 (pt) |
| KR (1) | KR102412803B1 (pt) |
| CN (1) | CN109069629B (pt) |
| AU (1) | AU2017241413B2 (pt) |
| BR (1) | BR112018069332A2 (pt) |
| CA (1) | CA3017714A1 (pt) |
| MX (1) | MX2018011133A (pt) |
| RU (1) | RU2755894C2 (pt) |
| WO (1) | WO2017170322A1 (pt) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| CN1638799A (zh) * | 2002-01-03 | 2005-07-13 | 唐纳士公司 | 人类肥大细胞表达的膜蛋白 |
| ATE551071T1 (de) * | 2006-09-08 | 2012-04-15 | Medimmune Llc | Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen |
| JP2008118915A (ja) * | 2006-11-10 | 2008-05-29 | Kazuto Nishio | 胃癌高発現遺伝子特定による胃癌診断および創薬への利用 |
| KR101174452B1 (ko) * | 2009-05-11 | 2012-08-16 | 한국생명공학연구원 | 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝 |
| EP2532365B1 (en) * | 2010-02-04 | 2016-05-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| EP2388336A1 (en) | 2010-05-19 | 2011-11-23 | Signature Diagnostics AG | Method and kits for diagnosing colorectal cancer |
-
2017
- 2017-03-27 EP EP17774859.7A patent/EP3437655A4/en active Pending
- 2017-03-27 RU RU2018137817A patent/RU2755894C2/ru active
- 2017-03-27 JP JP2017539053A patent/JP7037045B2/ja active Active
- 2017-03-27 BR BR112018069332A patent/BR112018069332A2/pt unknown
- 2017-03-27 US US16/088,502 patent/US11492410B2/en active Active
- 2017-03-27 CA CA3017714A patent/CA3017714A1/en active Pending
- 2017-03-27 AU AU2017241413A patent/AU2017241413B2/en active Active
- 2017-03-27 KR KR1020187030077A patent/KR102412803B1/ko active IP Right Grant
- 2017-03-27 MX MX2018011133A patent/MX2018011133A/es unknown
- 2017-03-27 WO PCT/JP2017/012239 patent/WO2017170322A1/ja active Application Filing
- 2017-03-27 CN CN201780019044.0A patent/CN109069629B/zh active Active
-
2022
- 2022-10-05 US US17/960,354 patent/US20230030982A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7037045B2 (ja) | 2022-03-16 |
| JPWO2017170322A1 (ja) | 2019-02-07 |
| EP3437655A1 (en) | 2019-02-06 |
| RU2018137817A3 (pt) | 2020-08-11 |
| EP3437655A4 (en) | 2019-11-13 |
| KR20180124954A (ko) | 2018-11-21 |
| AU2017241413A1 (en) | 2018-10-04 |
| CN109069629B (zh) | 2023-02-24 |
| AU2017241413B2 (en) | 2024-05-30 |
| RU2018137817A (ru) | 2020-04-29 |
| CA3017714A1 (en) | 2017-10-05 |
| KR102412803B1 (ko) | 2022-06-24 |
| US20190106505A1 (en) | 2019-04-11 |
| RU2755894C2 (ru) | 2021-09-22 |
| WO2017170322A1 (ja) | 2017-10-05 |
| US11492410B2 (en) | 2022-11-08 |
| US20230030982A1 (en) | 2023-02-02 |
| MX2018011133A (es) | 2019-01-14 |
| CN109069629A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112014021101A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo | |
| BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
| BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| AR110031A1 (es) | Métodos de tratamiento de pacientes con cáncer con inhibidores de farnesiltransferasa | |
| BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| BR112017010832A2 (pt) | composições de aminoácido para o tratamento de sintomas de doença | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| BR112017006969A2 (pt) | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno | |
| BR112019006174A2 (pt) | proteina terapêutica | |
| BR112019011350A2 (pt) | terapia de combinação | |
| EA201892322A1 (ru) | Способ лечения или предупреждения остеоартрита | |
| BR112020004935A2 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
| BR112017022390A2 (pt) | composição farmacêutica | |
| BR112020027063A2 (pt) | Tratamento de dor de cabeça com uso de anticorpos anti-cgrp | |
| BR112018069332A2 (pt) | composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |